Chronic drug abuse induces progressive changes to brain anatomy and physiology leading to impairments in executive function, emotional regulation, memory, and reward processing. The assessment of the extent to which these changes affect cognitive function necessitates objective, neurophysiological tools. The advent of advanced technologies, such as the BrainView quantitative electroencephalography (qEEG) discriminant database by Medeia Inc is positioned to provide a comprehensive approach to understanding altered cognitive processing related to chronic drug abuse. This platform leverages key biomarkers like the N100, P300, and N400 event-related potentials (ERPs) to identify electrophysiological abnormalities in the disrupted key neural circuits adversely affected by drug abuse, particularly those involving the prefrontal cortex, amygdala, hippocampus, and striatum. qEEG allows for the detection of structural and physiological disruptions via assessment of electrophysiological alterations in ERPs. ERPs, such as diminished P300 amplitudes, reflect deficits in attentional and cognitive control. The BrainView system’s ability to detect subtle changes in brain function makes it a critical tool for early diagnosis, monitoring the progression of cognitive dysfunction, and evaluating therapeutic interventions. With its extensive dataset, advanced statistical methods, and clinical focus, BrainView represents a transformative advancement in neurophysiology and neuropsychology, offering a comprehensive, efficient, and accurate solution for brain health assessments, ultimately paving the way for a new standard in clinical neuroassessment.